press releases 2006
-
December, 13 - Analysis by AlgoNomics reveals that Anticalins® intrinsically have an immunogenicity level comparable to the wild-type human lipocalin
-
October, 25 - Pieris confirms in vivo activity of potent VEGF specific Anticalin®
-
September, 27 - Crystallographic analysis of Anticalin® targeting CTLA-4 confirms the excellent suitability of Pieris’ lipocalin scaffold to develop superior biotherapeutics
-
July, 6 - Pieris reaches key milestones under the collaboration agreement with Syngenta
-
June, 21 - Pieris appoints Dr Andreas Hohlbaum as member of its management team
-
May, 17 - Pieris appoints new Chief Executive Officer
-
April, 21 - Pieris enters into a collaborative research and option agreement with GE Healthcare
previous press releases
-
March 10, 2004 - In vivo proof of concept for Anticalins®
-
May 7, 2004 - Pieris receives € 2 million grant from German Ministry of Education and Research (BMBF)
-
September 15, 2004 - Prof Arne Skerra, Dr Martin Pöhlchen and Dr Steffen Schlehuber nominated for the German Future Prize (Deutscher Zukunftspreis) 2004 of the German Federal President
-
July 24, 2003 - Pieris Proteolab AG and Technical University of Munich announce strategic alliance in Anticalin® research
-
November 18, 2003 - Pieris announces breakthrough in Anticalin® technology
-
January 24, 2002 - Pieris and CytoTools sign R&D collaboration agreement for the development of Anticalins®against novel targets in atherosclerosis
-
October 31, 2002 - Pieris Proteolab AG closes € 12 million financing round
-
July 19, 2001 - Pieris Proteolab AG appoints Chief Executive Officer
-
October 23, 2001 - Pieris wins award in the fifth round of the Biochance competition
-
November 5, 2001 - Pieris wins award during Biotech & Finance Conference in Paris
-
November 13, 2001 - Pieris releases human Anticalin®library with more than 10 billion structures
